12 / 16
Page 50
Notes:
conferenceseries
.com
Volume 8
Journal of Biotechnology & Biomaterials
ISSN: 2155-952X
Pharma Biotech 2018
December 10-11, 2018
December 10-11, 2018 | Rome, Italy
23
rd
International Conference on
Pharmaceutical Biotechnology
Recent Publications
1. Weissmann D, Underwood M, Salvetat N, Cavarec L and Vincent L (2016) Region specific alterations of A-to-I RNA
editin of serotonin 2c receptor in cortex of suicides with major depression. Translational Psychiatry 6(8):e878.
2. Van Der Laan S, Salvetat N, Weissmann D and Molina F (2017) Emerging RNA editing biomarkers will foster drug
development. Drug Discovery Today 22(7):1056-1063.
3. Cavarec L, Vincent L, Le Borgne C, Plusquellec C and Ollivier N (2013)
In Vitro
screening for drug-induced depression
and/or suicidal adverse effects: a new toxicogenomic assay based on CE-SSCP analysis of HTR2C mRNA editing in SH-
SY5Y cells. Neurotox Res. 23(1):49-62.
4. CambonK, Dos-SantosCouraR, Groc L, CarbonAandWeissmannD(2010)Aggressive behavior during social interaction
in mice is controlled by the modulation of tyrosine hydroxylase expression in the prefrontal cortex. Neuroscience
171(3):840-51..
Biography
Dinah Weissmann is an Executive Vice President atALCEDIAG’s, biotech company dedicated to the development of innovative diagnostics based on epigenetic biomarkers
mainly RNA editing. She is also Co-director of a public private laboratory, Sys2Diag that was created in 2015 and dedicated to the understanding of molecular basis of
complex diseases. Her research fields are mainly in neuroscience which leads to the discovery of a specific plasticity in adult brain coined phenotype plasticity that gave
rise to a novel class of antidepressant drugs. Later on, she focused on epigenetic mechanism understanding and developed new tests for diagnosis and management of
psychiatric patients as well as prediction of psychiatric adverse effects. She has 15 years of research experience as Director of Research at the CNRS (French academic
research institute) and has worked at various leader positions in pharma and biotech companies.
dweissmann@alcediag-alcen.com